Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.2 Million EUR | -50.09% |
| 2022 | -18.33 Million EUR | 28.47% |
| 2021 | -25.63 Million EUR | -38.07% |
| 2020 | -18.56 Million EUR | -79.12% |
| 2019 | -10.36 Million EUR | 11.21% |
| 2018 | -11.67 Million EUR | -8.55% |
| 2017 | -10.75 Million EUR | -69.04% |
| 2016 | -6.36 Million EUR | 2.39% |
| 2015 | -6.51 Million EUR | -16.86% |
| 2014 | -5.57 Million EUR | -12.35% |
| 2013 | -4.96 Million EUR | 44.29% |
| 2012 | -8.91 Million EUR | 33.42% |
| 2011 | -13.38 Million EUR | 42.09% |
| 2010 | -23.11 Million EUR | -79.66% |
| 2009 | -12.86 Million EUR | 39.87% |
| 2008 | -21.39 Million EUR | 10.59% |
| 2007 | -23.92 Million EUR | -31.11% |
| 2006 | -18.24 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.07 Million EUR | -10.92% |
| 2024 Q2 | -5.78 Million EUR | -14.1% |
| 2024 Q3 | -5.96 Million EUR | -3.06% |
| 2023 Q2 | -9.66 Million EUR | -45.56% |
| 2023 Q1 | -6.64 Million EUR | -3.51% |
| 2023 Q3 | -55.51 Thousand EUR | 99.43% |
| 2023 Q4 | -4.57 Million EUR | -8136.15% |
| 2023 FY | -27.51 Million EUR | -50.09% |
| 2022 Q4 | -6.41 Million EUR | -20.33% |
| 2022 Q1 | -7.08 Million EUR | 0.41% |
| 2022 Q2 | 736.47 Thousand EUR | 110.4% |
| 2022 Q3 | -5.33 Million EUR | -824.23% |
| 2022 FY | -18.33 Million EUR | 28.47% |
| 2021 Q1 | -6.28 Million EUR | -7.9% |
| 2021 Q3 | -5.59 Million EUR | 15.62% |
| 2021 Q4 | -7.11 Million EUR | -27.06% |
| 2021 Q2 | -6.63 Million EUR | -5.59% |
| 2021 FY | -25.63 Million EUR | -38.07% |
| 2020 Q1 | -4.56 Million EUR | -1.5% |
| 2020 FY | -18.56 Million EUR | -79.12% |
| 2020 Q2 | -4.84 Million EUR | -6.19% |
| 2020 Q3 | -3.04 Million EUR | 37.22% |
| 2020 Q4 | -5.82 Million EUR | -91.29% |
| 2019 FY | -10.36 Million EUR | 11.21% |
| 2019 Q1 | -3.08 Million EUR | 27.52% |
| 2019 Q2 | -1.24 Million EUR | 59.62% |
| 2019 Q3 | -1.31 Million EUR | -5.58% |
| 2019 Q4 | -4.49 Million EUR | -242.27% |
| 2018 Q1 | -2.41 Million EUR | 26.87% |
| 2018 Q2 | -2.29 Million EUR | 4.78% |
| 2018 FY | -11.67 Million EUR | -8.55% |
| 2018 Q4 | -4.25 Million EUR | -57.32% |
| 2018 Q3 | -2.7 Million EUR | -17.66% |
| 2017 FY | -10.75 Million EUR | -69.04% |
| 2017 Q3 | -3.3 Million EUR | -47.66% |
| 2017 Q4 | -3.3 Million EUR | 0.1% |
| 2017 Q2 | -2.23 Million EUR | -17.24% |
| 2017 Q1 | -1.9 Million EUR | 15.12% |
| 2016 Q2 | -1.3 Million EUR | -22.13% |
| 2016 Q3 | -1.73 Million EUR | -32.98% |
| 2016 FY | -6.36 Million EUR | 2.39% |
| 2016 Q1 | -1.06 Million EUR | 64.4% |
| 2016 Q4 | -2.24 Million EUR | -29.5% |
| 2015 Q2 | -824 Thousand EUR | 23.3% |
| 2015 FY | -6.51 Million EUR | -16.86% |
| 2015 Q1 | -1.07 Million EUR | 72.2% |
| 2015 Q4 | -3 Million EUR | -85.99% |
| 2015 Q3 | -1.61 Million EUR | -96.0% |
| 2014 FY | -5.57 Million EUR | -12.35% |
| 2014 Q4 | -3.86 Million EUR | -248.73% |
| 2014 Q3 | 2.59 Million EUR | 280.17% |
| 2014 Q2 | -1.44 Million EUR | 49.72% |
| 2014 Q1 | -2.86 Million EUR | -168.01% |
| 2013 Q4 | -1.07 Million EUR | -165.53% |
| 2013 FY | -4.96 Million EUR | 44.29% |
| 2013 Q1 | -1.94 Million EUR | -0.23% |
| 2013 Q2 | -1.54 Million EUR | 20.74% |
| 2013 Q3 | -403 Thousand EUR | 73.88% |
| 2012 FY | -8.91 Million EUR | 33.42% |
| 2012 Q1 | -2.37 Million EUR | -357.85% |
| 2012 Q2 | -2.91 Million EUR | -22.54% |
| 2012 Q3 | -1.67 Million EUR | 42.34% |
| 2012 Q4 | -1.94 Million EUR | -15.68% |
| 2011 Q1 | -5.88 Million EUR | -0.15% |
| 2011 Q3 | -2.46 Million EUR | 45.49% |
| 2011 Q2 | -4.51 Million EUR | 23.26% |
| 2011 FY | -13.38 Million EUR | 42.09% |
| 2011 Q4 | -519.02 Thousand EUR | 78.92% |
| 2010 FY | -23.11 Million EUR | -79.66% |
| 2010 Q2 | -6.15 Million EUR | -13.97% |
| 2010 Q3 | -5.67 Million EUR | 7.95% |
| 2010 Q1 | -5.4 Million EUR | -223.45% |
| 2010 Q4 | -5.87 Million EUR | -3.64% |
| 2009 Q4 | -1.67 Million EUR | -165.15% |
| 2009 Q3 | -630.22 Thousand EUR | 86.74% |
| 2009 Q2 | -4.75 Million EUR | 18.23% |
| 2009 Q1 | -5.81 Million EUR | 0.0% |
| 2009 FY | -12.86 Million EUR | 39.87% |
| 2008 FY | -21.39 Million EUR | 10.59% |
| 2007 FY | -23.92 Million EUR | -31.11% |
| 2006 FY | -18.24 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 103.072% |
| CureVac N.V. | -274.2 Million EUR | 92.265% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 114.78% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 114.78% |
| BRAIN Biotech AG | -6.71 Million EUR | -215.857% |
| Formycon AG | -369 Thousand EUR | -5647.913% |
| Medigene AG | -16.14 Million EUR | -31.338% |